OnePin Peptide Library · Metabolic
Survodutide
BI 456906
Survodutide (BI 456906) is an investigational dual agonist peptide targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. Unlike pure GLP-1 receptor agonists (such as semaglutide), survodutide's dual mechanism is designed to produce weight loss through both appetite suppression (GLP-1 component) and increased energy expenditure and hepatic fat oxidation (glucagon component).,Survodutide is in Phase 3 clinical development for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). In Phase 2 trials, survodutide demonstrated substantial weight loss - up to 18-19% body weight reduction at the highest doses over 46 weeks - along with significant improvements in liver fat content and markers of liver fibrosis. These results position it as a potentially differentiated option in the incretin-based obesity treatment landscape.,The glucagon receptor agonism component distinguishes survodutide from other GLP-1-based therapies. While glucagon raises blood sugar (potentially counterproductive), the GLP-1 component offsets this, and the net metabolic effect includes enhanced lipid oxidation, increased energy expenditure, and improved body composition. Boehringer Ingelheim's Phase 3 SYNCHRONIZE program is evaluating survodutide across multiple metabolic indications.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Activates GLP-1 receptors in the brain (hypothalamus and brainstem) to reduce appetite, slow gastric emptying, and enhance satiety signaling, producing significant caloric intake reduction.,Activates glucagon receptors in the liver and adipose tissue, promoting hepatic fat oxidation, increasing energy expenditure, and mobilizing lipid stores - effects not achieved by GLP-1 agonism alone.,The dual agonist mechanism produces synergistic weight loss: GLP-1 reduces food intake while glucagon increases energy expenditure, targeting both sides of the energy balance equation.
Activates GLP-1 receptors in the brain (hypothalamus and brainstem) to reduce appetite, slow gastric emptying, and enhance satiety signaling, producing significant caloric intake reduction.,Activates glucagon receptors in the liver and adipose tissue, promoting hepatic fat oxidation, increasing energy expenditure, and mobilizing lipid stores - effects not achieved by GLP-1 agonism alone.,The dual agonist mechanism produces synergistic weight loss: GLP-1 reduces food intake while glucagon increases energy expenditure, targeting both sides of the energy balance equation.
What to expect
Weeks 1-4: Reduced appetite and early weight loss during dose titration. GI side effects most common in this phase.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Pharmacokinetics
Storage. Store refrigerated at 2-8C. Do not freeze. Protect from light.
Regulatory status
Investigational - not yet approved by FDA or any regulatory agency. Phase 3 clinical trials ongoing (SYNCHRONIZE program by Boehringer Ingelheim). Breakthrough Therapy designation for MASH.
Put it to work
Calculate, log & track
Open Survodutide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Survodutide in the app →Go deeper
The guide & community
The complete Survodutide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗